CN110831927B - 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物 - Google Patents

苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物 Download PDF

Info

Publication number
CN110831927B
CN110831927B CN201880033126.5A CN201880033126A CN110831927B CN 110831927 B CN110831927 B CN 110831927B CN 201880033126 A CN201880033126 A CN 201880033126A CN 110831927 B CN110831927 B CN 110831927B
Authority
CN
China
Prior art keywords
methyl
amino
compound
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880033126.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110831927A (zh
Inventor
M.M.西富恩特斯-加西亚
M.C.加西亚-帕雷德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilai Co
Original Assignee
Lilai Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilai Co filed Critical Lilai Co
Priority to CN202310753648.5A priority Critical patent/CN117510405A/zh
Publication of CN110831927A publication Critical patent/CN110831927A/zh
Application granted granted Critical
Publication of CN110831927B publication Critical patent/CN110831927B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
CN201880033126.5A 2017-04-18 2018-04-11 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物 Active CN110831927B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310753648.5A CN117510405A (zh) 2017-04-18 2018-04-11 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18
EP17382207.3 2017-04-18
PCT/US2018/027005 WO2018194885A1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310753648.5A Division CN117510405A (zh) 2017-04-18 2018-04-11 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物

Publications (2)

Publication Number Publication Date
CN110831927A CN110831927A (zh) 2020-02-21
CN110831927B true CN110831927B (zh) 2023-07-14

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880033126.5A Active CN110831927B (zh) 2017-04-18 2018-04-11 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物
CN202310753648.5A Pending CN117510405A (zh) 2017-04-18 2018-04-11 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310753648.5A Pending CN117510405A (zh) 2017-04-18 2018-04-11 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物

Country Status (30)

Country Link
US (2) US11655214B2 (https=)
EP (2) EP4039675B1 (https=)
JP (2) JP7110232B2 (https=)
KR (2) KR102575246B1 (https=)
CN (2) CN110831927B (https=)
AU (2) AU2018255191B2 (https=)
BR (1) BR112019021867A2 (https=)
CO (1) CO2019012767A2 (https=)
CR (1) CR20190519A (https=)
CY (1) CY1125150T1 (https=)
DK (2) DK4039675T3 (https=)
ES (2) ES2906847T3 (https=)
FI (1) FI4039675T3 (https=)
HR (2) HRP20241188T1 (https=)
HU (2) HUE057745T2 (https=)
IL (2) IL270005B (https=)
LT (2) LT3612519T (https=)
MX (2) MX389724B (https=)
MY (1) MY199442A (https=)
NZ (1) NZ758291A (https=)
PH (1) PH12019502363B1 (https=)
PL (2) PL4039675T3 (https=)
PT (2) PT4039675T (https=)
RS (2) RS65914B1 (https=)
SA (1) SA519410320B1 (https=)
SG (1) SG11201909680UA (https=)
SI (2) SI4039675T1 (https=)
SM (2) SMT202200100T1 (https=)
WO (1) WO2018194885A1 (https=)
ZA (1) ZA201906811B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65914B1 (sr) * 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja
CA3095156A1 (en) * 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
US12331054B2 (en) 2019-08-29 2025-06-17 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
WO2021041976A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
CN114585606A (zh) * 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
CA3152508A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
CN121399099A (zh) * 2023-03-30 2026-01-23 希伯塞尔股份有限公司 (r)-2-氨基-5-(4-(2-(3,5-二氟苯基)-2-羟基乙酰胺基)-2-甲基苯基)-n-异丙基烟酰胺的晶形及其使用方法
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1812973A (zh) * 2002-01-25 2006-08-02 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吲唑化合物
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
CN102816113A (zh) * 2003-07-23 2012-12-12 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
WO2005030933A2 (en) 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
WO2010080992A1 (en) 2009-01-09 2010-07-15 The Trustees Of The University Of Pennsylvania Regulators of the interferon-alpha receptor 1 (ifnar1) chain of the interferon receptor
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
EP2986286A1 (en) 2013-04-15 2016-02-24 Universita' Degli Studi di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
JP6493218B2 (ja) 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
KR102562866B1 (ko) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CN108026102A (zh) * 2015-07-24 2018-05-11 蓝印药品公司 可用于治疗与kit和pdgfr相关的病症的化合物
ES2965081T3 (es) 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
US20190241573A1 (en) 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
EP3656382A1 (en) 2017-01-30 2020-05-27 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
RS65914B1 (sr) 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
CA3095156A1 (en) 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
EP3860578A1 (en) 2018-10-01 2021-08-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1812973A (zh) * 2002-01-25 2006-08-02 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吲唑化合物
CN102816113A (zh) * 2003-07-23 2012-12-12 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物

Also Published As

Publication number Publication date
US11655214B2 (en) 2023-05-23
KR20190140966A (ko) 2019-12-20
US20230373922A1 (en) 2023-11-23
LT3612519T (lt) 2022-03-25
SMT202200100T1 (it) 2022-03-21
PL3612519T3 (pl) 2022-05-02
LT4039675T (lt) 2024-10-10
JP7110232B2 (ja) 2022-08-01
SA519410320B1 (ar) 2022-05-08
RS65914B1 (sr) 2024-10-31
US12590064B2 (en) 2026-03-31
ES2988739T3 (es) 2024-11-21
RS62933B1 (sr) 2022-03-31
EP4039675B1 (en) 2024-06-12
MX2019012428A (es) 2022-01-28
JP7331212B2 (ja) 2023-08-22
PH12019502363B1 (en) 2023-11-15
AU2018255191A1 (en) 2019-11-07
RU2019136694A (ru) 2021-05-18
HUE057745T2 (hu) 2022-06-28
EP3612519B1 (en) 2021-12-01
DK4039675T3 (da) 2024-09-02
EP4039675A1 (en) 2022-08-10
MX389724B (es) 2025-03-20
AU2022206702B2 (en) 2024-04-11
ES2906847T3 (es) 2022-04-20
AU2022206702A1 (en) 2022-08-11
ZA201906811B (en) 2021-01-27
CO2019012767A2 (es) 2020-04-01
JP2021517555A (ja) 2021-07-26
MY199442A (en) 2023-10-28
SMT202400357T1 (it) 2024-11-15
NZ758291A (en) 2025-11-28
KR20230129627A (ko) 2023-09-08
MX2022001310A (es) 2022-03-02
PH12019502363A1 (en) 2020-12-07
CA3060564A1 (en) 2018-10-25
SG11201909680UA (en) 2019-11-28
KR102575246B1 (ko) 2023-09-06
JP2022141835A (ja) 2022-09-29
BR112019021867A2 (pt) 2020-05-26
WO2018194885A1 (en) 2018-10-25
FI4039675T3 (fi) 2024-09-10
AU2018255191B2 (en) 2022-04-21
HRP20220263T1 (hr) 2022-04-29
RU2019136694A3 (https=) 2021-05-19
CY1125150T1 (el) 2023-06-09
IL288822A (en) 2022-02-01
PT4039675T (pt) 2024-09-16
CN117510405A (zh) 2024-02-06
EP3612519A1 (en) 2020-02-26
SI3612519T1 (sl) 2022-04-29
IL288822B2 (en) 2023-06-01
HUE068023T2 (hu) 2024-12-28
US20210114985A1 (en) 2021-04-22
SI4039675T1 (sl) 2024-10-30
PT3612519T (pt) 2022-02-22
IL270005B (en) 2022-01-01
HRP20241188T1 (hr) 2024-12-06
PL4039675T3 (pl) 2025-01-07
CR20190519A (es) 2020-03-06
DK3612519T3 (da) 2022-03-07
CN110831927A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
CN110831927B (zh) 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物
CN107108580B (zh) 吲哚酮化合物及其用途
CN107074778A (zh) 苯并咪唑类似物和相关方法
CN107531683A (zh) Usp7抑制剂化合物及使用方法
AU2015336458A1 (en) KCNQ2-5 channel activator
CN113336774B (zh) 作为trk抑制剂的取代的手性二芳基大环化合物
CN107383019A (zh) 吡唑并[4,3‑h]喹唑啉类化合物及其用途
JP6850396B2 (ja) ［１，２，４］トリアゾロ［４，３−ａ］ピラジン−６（５ｈ）−オン誘導体
HK40079392B (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
RU2804280C2 (ru) Фенил-2-гидрокси-ацетиламино-2-метил-фениловые соединения
HK40079392A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40024453B (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40024453A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
CA3060564C (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
KR20250041906A (ko) Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물
CN121001994A (zh) Atm激酶抑制剂
CN109942562A (zh) 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40024453

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant